NeoTX Therapeutics

NeoTX Therapeutics Ltd. is a biopharmaceutical company focused on developing innovative anticancer immunotherapies through its Selective T cell Redirection (STR) platform. This technology attaches a genetically engineered bacterial determinant to the surface of tumors, activating immune cells in a way that enhances the body's natural immune response while circumventing the suppressive tumor environment. By transforming a weak immune response into a robust and safe antibacterial reaction, NeoTX aims to provide healthcare professionals with effective treatment options for cancer patients. Established in 2004 and headquartered in Rehovot, Israel, the company emphasizes research and development to build a unique product pipeline, leveraging both internal efforts and collaborative partnerships.